Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. (ARVN) is a clinical-stage biopharmaceutical leader pioneering targeted protein degradation through its PROTAC® technology. This news hub provides investors and researchers with essential updates on therapeutic developments, strategic collaborations, and clinical milestones.
Access authoritative reporting on ARVN's oncology and neurodegenerative disease programs, including estrogen receptor degraders for breast cancer and novel neurological candidates. Our curated news collection features:
• Clinical trial developments
• Research collaborations
• Regulatory milestones
• Scientific presentations
Bookmark this page for real-time updates on ARVN's progress in addressing previously undruggable targets through innovative protein degradation approaches. Verify information directly through official company communications and SEC filings.
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, will have its Chief Scientific Officer Ian Taylor and Chief Financial Officer Sean Cassidy participate in a fireside chat during the Stifel Targeted Oncology Day on April 26, 2023, at 11:30 a.m. ET. The event will be available via a live audio webcast, accessible from Arvinas' website. The company aims to develop therapies that degrade disease-causing proteins and currently has three investigational clinical-stage programs. These programs include bavdegalutamide and ARV-766 for prostate cancer treatment, as well as ARV-471 for breast cancer. The company uses its proprietary PROTAC Discovery Engine to engineer targeted protein degraders.
Arvinas, Inc. (Nasdaq: ARVN) has appointed Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership. With over 25 years in the pharmaceutical industry, including significant experience in oncology from her previous role at AstraZeneca, Ms. Page is expected to enhance Arvinas' Executive Committee. Her expertise spans research to commercialization, which may strengthen the company’s focus on developing targeted protein degradation therapeutics. This leadership change aligns with Arvinas' commitment to advancing its clinical-stage oncology programs, including those for prostate and breast cancers.
FAQ
What is the current stock price of Arvinas (ARVN)?
What is the market cap of Arvinas (ARVN)?
